Sugi Predict

Sugi Predict / Compounds / SCHEMBL21748609

SCHEMBL21748609

SCHEMBL21748609

CC(C)(COc1ccc(Cl)cc1)C(=O)O

nearest known ligand 0.62

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ MAP4K4 O95819 1/20 0.62
▸ PPARA Q07869 7/20 0.58
▸ MEN1 O00255 1/20 0.56
▸ CYP1A2 P05177 1/20 0.56
▸ CYP3A4 P08684 1/20 0.56
▸ CYP2D6 P10635 1/20 0.56
▸ MAPT P10636 1/20 0.56
▸ CYP2C19 P33261 1/20 0.56
▸ KMT2A Q03164 1/20 0.56
▸ SSTR4 P31391 1/20 0.52
▸ DGAT1 O75907 7/20 0.52
▸ PPARG P37231 3/20 0.49
▸ FABP2 P12104 1/20 0.49
▸ SLC22A12 Q96S37 1/20 0.49
▸ CYP2C9 P11712 1/20 0.47
▸ NR4A2 P43354 1/20 0.46
▸ PPARD Q03181 2/20 0.46
▸ MAOA P21397 1/20 0.45
▸ MAOB P27338 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21991957 0.95 MAP4K4 (0.58) MAP4K4PPARAMEN1CYP1A2CYP3A4
SCHEMBL21991555 0.92 PPARA (0.61) MAP4K4PPARAMEN1CYP1A2CYP3A4
SCHEMBL21991969 0.91 NR4A2 (0.61) MAP4K4PPARAPPARGNR4A2MAOA
SCHEMBL21992667 0.86 L3MBTL1 (0.55) MAP4K4PPARAMEN1CYP1A2CYP3A4
SCHEMBL10390840 0.86 SSTR4 (0.52) MAP4K4PPARAMEN1CYP1A2CYP3A4
SCHEMBL1148134 0.86 PPARA (0.56) MAP4K4PPARAMEN1CYP1A2CYP3A4
SCHEMBL21991543 0.84 PPARA (0.57) MAP4K4PPARAMAPTDGAT1CYP2C9
SCHEMBL13948414 0.84 CYP2C9 (0.61) MAP4K4PPARACYP1A2DGAT1PPARG
SCHEMBL5724626 0.83 PPARA (0.58) MAP4K4PPARASSTR4DGAT1PPARG
SCHEMBL21748570 0.83 SSTR4 (0.53) MAP4K4PPARAMEN1CYP1A2CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250049772-A1 PIPERIDINYL-3-(ARYLOXY)PROPANAMIDES AND PROPANOATES TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2025-02-13 — — US disclosed
US-12005054-B2 Piperidinyl-3-(aryloxy)propanamides and propanoates TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2024-06-11 — — US disclosed
CN-112236423-B Piperidinyl-3- (aryloxy) propanamides and propionic acid esters 武田药品工业株式会社 2024-02-06 — — CN disclosed
US-20230021834-A1 PIPERIDINYL-3-(ARYLOXY)PROPANAMIDES AND PROPANOATES TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2023-01-26 — — US disclosed
US-20230021834-A1 PIPERIDINYL-3-(ARYLOXY)PROPANAMIDES AND PROPANOATES TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2023-01-26 — — US disclosed
US-20220409566-A1 CCL5 Inhibitors LAPKO INC, dba AFECTA PHARMACEUTICALS 2022-12-29 — — US disclosed
US-20220142961-A1 CCL5 Inhibitors LAPKO INC, dba AFECTA PHARMACEUTICALS 2022-05-12 — — US disclosed
US-11318111-B2 CCL5 inhibitors LAPKO INC (US) 2022-05-03 — — US disclosed
US-20210196665-A1 CCL5 Inhibitors AFECTA PHARMACEUTICALS, INC. (US) 2021-07-01 — — US disclosed
US-11045457-B2 Piperidinyl-3-(aryloxy)propanamides and propanoates TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2021-06-29 — — US disclosed
US-11045457-B2 Piperidinyl-3-(aryloxy)propanamides and propanoates TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2021-06-29 — — US disclosed
US-10940132-B2 CCL5 inhibitors AFECTA PHARMACEUTICALS, INC. (US) 2021-03-09 — — US disclosed
CN-112236423-A Piperidinyl-3- (aryloxy) propanamides and propionates 武田药品工业株式会社 2021-01-15 — — CN disclosed
EP-3759094-A1 PIPERIDINYL-3-(ARYLOXY)PROPANAMIDES AND PROPANOATES Takeda Pharmaceutical Company Limited (JP) 2021-01-06 — — EP disclosed
US-20200138766-A1 CCL5 INHIBITORS LAPKO INC. DBA AFECTA PHARMACEUTICALS 2020-05-07 — — US disclosed
US-20200061041-A1 PIPERIDINYL-3-(ARYLOXY)PROPANAMIDES AND PROPANOATES TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2020-02-27 — — US disclosed
US-20200061041-A1 PIPERIDINYL-3-(ARYLOXY)PROPANAMIDES AND PROPANOATES TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2020-02-27 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220142961-A1 CCL5 Inhibitors CCL5, CCL11, CCR5 MAP4K4 2952/4885PPARA 806/4885MEN1 3749/4885
US-20200138766-A1 CCL5 INHIBITORS CCL5, CCL11, CCR5 MAP4K4 2952/4885PPARA 806/4885MEN1 3749/4885
US-11045457-B2 Piperidinyl-3-(aryloxy)propanamides and propanoates SSTR4, SSTR3, NPY4R MAP4K4 2530/4885PPARA 1267/4885MEN1 1736/4885
US-12005054-B2 Piperidinyl-3-(aryloxy)propanamides and propanoates SSTR4, SSTR3, NPY4R MAP4K4 2530/4885PPARA 1267/4885MEN1 1736/4885
US-20250049772-A1 PIPERIDINYL-3-(ARYLOXY)PROPANAMIDES AND PROPANOATES SSTR4, SSTR3, NPY4R MAP4K4 2530/4885PPARA 1267/4885MEN1 1736/4885
US-20210196665-A1 CCL5 Inhibitors CCL5, CCL11, CCR5 MAP4K4 2952/4885PPARA 806/4885MEN1 3749/4885
US-20200061041-A1 PIPERIDINYL-3-(ARYLOXY)PROPANAMIDES AND PROPANOATES SSTR4, SSTR3, NPY4R MAP4K4 2530/4885PPARA 1267/4885MEN1 1736/4885
US-10940132-B2 CCL5 inhibitors CCL5, CCL11, CCR5 MAP4K4 2952/4885PPARA 806/4885MEN1 3749/4885
US-11318111-B2 CCL5 inhibitors CCL5, CCL11, CCR5 MAP4K4 2952/4885PPARA 806/4885MEN1 3749/4885
US-20220409566-A1 CCL5 Inhibitors CCL5, CCL11, CCR5 MAP4K4 2952/4885PPARA 806/4885MEN1 3749/4885
US-20230021834-A1 PIPERIDINYL-3-(ARYLOXY)PROPANAMIDES AND PROPANOATES SSTR4, SSTR3, NPY4R MAP4K4 2530/4885PPARA 1267/4885MEN1 1736/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.